MRA Advisory Group Purchases New Shares in Halozyme Therapeutics, Inc. $HALO

Key Points

• MRA Advisory Group has acquired 8,721 shares of Halozyme Therapeutics, valued at approximately $454,000, indicating growing interest from institutional investors.
• Insider trading activity included CEO Helen Torley and CFO Nicole Labrosse selling 20,000 shares each, reducing their ownership stakes.
• Analysts are optimistic about Halozyme Therapeutics, with several raising price targets and ratings, leading to a consensus average target price of $67.11.

MRA Advisory Group acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 8,721 shares of the biopharmaceutical company's stock, valued at approximately $454,000.

A number of other large investors have also added to or reduced their stakes in the stock. Strs Ohio purchased a new stake in Halozyme Therapeutics during the first quarter worth about $1,914,000. Acadian Asset Management LLC purchased a new stake in Halozyme Therapeutics during the first quarter worth about $195,000. Intech Investment Management LLC increased its holdings in Halozyme Therapeutics by 9.9% during the first quarter. Intech Investment Management LLC now owns 153,199 shares of the biopharmaceutical company's stock worth $9,776,000 after buying an additional 13,789 shares during the last quarter. Focus Partners Wealth increased its holdings in Halozyme Therapeutics by 57.8% during the first quarter. Focus Partners Wealth now owns 120,815 shares of the biopharmaceutical company's stock worth $7,709,000 after buying an additional 44,260 shares during the last quarter. Finally, Empowered Funds LLC purchased a new stake in Halozyme Therapeutics during the first quarter worth about $755,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $74.44, for a total transaction of $1,488,800.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares in the company, valued at $54,618,042.36. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Nicole Labrosse sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the sale, the chief financial officer owned 24,306 shares of the company's stock, valued at approximately $1,840,207.26. The trade was a 45.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 124,000 shares of company stock worth $7,830,320 over the last three months. 2.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Morgan Stanley raised their price objective on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an "overweight" rating in a report on Monday, August 18th. JMP Securities raised their price objective on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a report on Wednesday, August 6th. Zacks Research upgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Finally, The Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a "neutral" rating and a $55.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics presently has an average rating of "Hold" and a consensus price target of $67.11.

Halozyme Therapeutics Price Performance

HALO stock opened at $76.90 on Monday. The firm has a 50 day moving average of $65.11 and a 200-day moving average of $60.49. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $77.60. The firm has a market capitalization of $8.99 billion, a P/E ratio of 17.60, a price-to-earnings-growth ratio of 0.42 and a beta of 1.19.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating analysts' consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. During the same period last year, the business earned $0.91 earnings per share. Halozyme Therapeutics's revenue was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.